Literature DB >> 15314550

Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and Anti-CD28 antibodies.

Dale Kalamasz1, S A Long, Ruth Taniguchi, Jane H Buckner, Ronald J Berenson, Mark Bonyhadi.   

Abstract

T-cell receptor engagement and accompanying costimulatory signals control the level of activation and functional potential of individual T cells. The authors previously developed a novel technology in which human T cells are activated and expanded in culture ex vivo using anti-CD3 and anti-CD28 monoclonal antibodies covalently linked to superparamagnetic beads (Xcyte Dynabeads). In this study the addition of N-acetyl L-cysteine (NAC) to the cultures markedly increased the expansion of T cells from human peripheral blood mononuclear cells without diminishing cell function. NAC increased the rate of T-cell division, reduced apoptosis, and increased the percentage of antigen-specific memory T cells in the cultures. The effect of varying the ratio of beads to T cells (1:10-10:1) at culture initiation was also evaluated. Polyclonal T cells were expanded at all bead-to-T cell ratios tested (range 1:10-10:1). While high bead-to-T cell ratios (5:1 and 10:1) deleted, low ratios (1:10 and 1:5) preserved memory T cells directed against cytomegalovirus, Epstein-Barr virus, and influenza virus antigens. Adding more anti-CD3/anti-CD28 beads during the culture led to further expansion of T cells. Experiments also revealed that reducing the amount of anti-CD3 antibodies relative to the amount of anti-CD28 antibodies on the beads favored the proliferation of antigen-specific T cells. In summary, these data indicate that T cell-stimulating effects of anti-CD3/anti-CD28 beads can be further manipulated to control the expansion of antigen-specific memory T cells and can be used to rapidly expand antigen-specific T cells ex vivo for potential clinical applications. Copyright 2004 Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15314550     DOI: 10.1097/00002371-200409000-00010

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  33 in total

1.  T cell receptor-transgenic primary T cells as a tool for discovery of leukaemia-associated antigens.

Authors:  R Ivanov; S Hol; T I Aarts; A Hagenbeek; S B Ebeling
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

Review 2.  Post-transplant adoptive T-cell immunotherapy.

Authors:  Nicole A Aqui; Carl H June
Journal:  Best Pract Res Clin Haematol       Date:  2008-09       Impact factor: 3.020

3.  Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes.

Authors:  Sebastian Newrzela; Kerstin Cornils; Tim Heinrich; Julia Schläger; Ji-Hee Yi; Olga Lysenko; Janine Kimpel; Boris Fehse; Dorothee von Laer
Journal:  Mol Med       Date:  2011-07-27       Impact factor: 6.354

4.  Efficacy of Adoptive T-cell Therapy Is Improved by Treatment with the Antioxidant N-Acetyl Cysteine, Which Limits Activation-Induced T-cell Death.

Authors:  Matthew J Scheffel; Gina Scurti; Patricia Simms; Elizabeth Garrett-Mayer; Shikhar Mehrotra; Michael I Nishimura; Christina Voelkel-Johnson
Journal:  Cancer Res       Date:  2016-10-15       Impact factor: 12.701

5.  Cationic polymers for non-viral gene delivery to human T cells.

Authors:  Brynn R Olden; Yilong Cheng; Jonathan L Yu; Suzie H Pun
Journal:  J Control Release       Date:  2018-03-05       Impact factor: 9.776

6.  Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD/SCID beta2mnull mice.

Authors:  Bruno Nervi; Michael P Rettig; Julie K Ritchey; Hanlin L Wang; Gerhard Bauer; Jon Walker; Mark L Bonyhadi; Ronald J Berenson; Julie L Prior; David Piwnica-Worms; Jan A Nolta; John F DiPersio
Journal:  Exp Hematol       Date:  2007-08-30       Impact factor: 3.084

7.  Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.

Authors:  Daniel Hollyman; Jolanta Stefanski; Mark Przybylowski; Shirley Bartido; Oriana Borquez-Ojeda; Clare Taylor; Raymond Yeh; Vanessa Capacio; Malgorzata Olszewska; James Hosey; Michel Sadelain; Renier J Brentjens; Isabelle Rivière
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456

Review 8.  Principles of adoptive T cell cancer therapy.

Authors:  Carl H June
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

9.  Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells.

Authors:  Baldev Vasir; Zekui Wu; Keith Crawford; Jacalyn Rosenblatt; Corrine Zarwan; Adam Bissonnette; Donald Kufe; David Avigan
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

10.  Comparison of polyclonal expansion methods to improve the recovery of cervical cytobrush-derived T cells from the female genital tract of HIV-infected women.

Authors:  Alfred Bere; Lynette Denny; Willem Hanekom; Wendy A Burgers; Jo-Ann S Passmore
Journal:  J Immunol Methods       Date:  2010-02-08       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.